AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
Phase 3positiveSKYRIZIPositive
AI Analysis
Summary
AbbVie announced positive topline results from the Phase 3 AFFIRM study evaluating SKYRIZI (risankizumab) subcutaneous induction in patients with Crohn's disease. The successful Phase 3 readout represents a key milestone for the drug candidate in this indication.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Positive topline results from AFFIRM Phase 3 study
Importance:8/10
Sentiment:
0.85
Phase_3Crohn's_diseaseRisankizumabImmunologyPositive_data
Related Companies
Read the original article
Published by yahoo_finance on March 2, 2026 1:30 PM